The cost-effectiveness of treatment of age-related macular degeneration: A review

Minerva Medica

Volumn 100, Issue 1, 2009, Pages 69-77

  Kymes, Steven M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Eye diseases; Macular degeneration; Retina

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HUMAN; PHOTODYNAMIC THERAPY; PREVALENCE; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION;

EID: 66449092544     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Brown A, Hodge W, Kymes SM, Creuss A, Blackhouse G, Morrison A et al. Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation (Technology Report #10). Ottawa: Canadian Agency for Drugs and Technology in Health, 2008.
2. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT et al. Prevalence of age-related macular degeneration in the United States.[see comment]. Arch Ophthalmol 2004;122:564-572
3. World Health Organization. Prevention of Blindness and Visual Impairment: Age-related Macular Degneration. http:/www.who.int/blindness/causes/priority/ en/index8.html. Accessed January 18, 2009.
4. Rosario Brancato. Studio epidemiologico e genetico della degenerazione maculare senile. http://www.ricer-caitaliana.it/prin/dettaglio-prin-en- 2004062898.htm. Accessed January 18, 2009.
5. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.[see comment]. Arch Ophthalmol 2001;119:1417-1436
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal chorodial neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol 2001;119:198-207.
7. Royal National Institute of Blind People. New Anti-VEGF treatments for wet AMD. http://www.mib.org.uk/xpedio/groups/public/documents/publicwebsite/ public-antivegf.hcsp. Accessed January 18, 2009.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816
9. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
11. Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F et al. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study. Eur J Health Econ 2004;5:22-27
12. Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N et al. The economic burden of major adult visual disorders in the United States.[erratum appears in Arch Ophthalmol. 2007 Sep;125(9):1304]. Arch Ophthalmol 2006;124:1754-1760
13. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-1204
14. Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K et al. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy. Drugs Aging 2008;25:255-268
15. Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A et al. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 2008;26:57-73.
16. Ruiz-Moreno JM, Coco RM, Garcia-Arumi J, Xu X, Zlateva G. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin 2008;24:2103-2111
17. Bonastre J, Le Pen C, Soubrane G, Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181-190 (Pubitemid 36286662)
18. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001;108:1893-1901
19. Coleman AL, Stone K, Ewing SK, Nevitt M, Cummings S, Cauley JA et al. Higher risk of multiple falls among elderly women who lose visual acuity. Ophthalmology 2004:111:857-862
20. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual Impairment and Falls in Older Adults: The Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58-64.
21. Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC, Rimal R et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol 2007;144:238-244
22. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544-550 (Pubitemid 46596727)
23. AHRQ - Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey - MEPS. [cited 2009 February 2]. Available at: http://www.meps. ahrq.gov/mepsweb/about-meps/survey-back.jsp
24. Age-Related Eye Disease Study Research G. The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No. 1. Control Clin Trials 1999;20:573-600.
25. Rein DB, Saaddine JB, Wittenborn JS, Wirth KE, Hoerger TJ, Narayan KM et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology 2007;114:1319-1326
26. Hopley C, Salkeld G, Wang JJ, Mitchell P. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004:88:450-454 (Pubitemid 38437856)
27. Wailoo A, Roberts J, Brazier J, McCabe C. Efficiency, equity, and NICE clinical guidelines. BMJ 2004;328:536-537
28. Gillick MR. Medicare Coverage for Technological Innovations - Time for New Criteria? N Engl J Med 2004;350:2199-2203
29. Kymes SM, Lee BS. Preference-based quality of life measures in people with visual impairment. Optom Vis Sci 2007;84:809-816 (Pubitemid 47262992)
30. Evans JR, Henshaw K. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews 2008.
31. Belanger C, Burling JE, Cook N, Eberlein K, Goldhaber SZ, Gordon D. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-135 (Pubitemid 19180675)
32. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995;62 (Suppl):1427S-30S.
33. Garrett SK, McNeil JJ, Silagy C, Sinclair M, Thomas AP, Robman LP et al. Methodology of the VECAT study: Vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiol 1999;6:195-208.
34. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology' 2001;108:2051-2059 (Pubitemid 33032778)
35. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001;16:218-222
36. Kymes SM. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases. Ophthalmic Epidemiol 2008;15:76-83.
37. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment (Winchester. England) 2003;7:v-vi. (Pubitemid 37321488)
38. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-987 (Pubitemid 39013134)
39. Smith DH, Fenn P, Drammond MF. Cost-effectiveness of photodynamic threrapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol 2004;88:1107-1112 (Pubitemid 39141365)
40. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 2008;12:iii-iv.
41. Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007;29:2096-106;discussion 2094-2095 (Pubitemid 350212796)
42. Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics 2007:25:863-879 (Pubitemid 47481636)
43. Neubauer AS, Holz FG, Schrader W, Back EI, Kuhn T, Kampik A et al. Was darf Lebensqualitat kosten? Kosten-Nutzwertanalyse von Ranibizumab (Lucentis) bei altersabhangiger Makuladegeneration. Klin Monatsbl Augenheilkd 2007;224:727-732
44. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007;114:1170-1178 (Pubitemid 46829369)
45. Kymes SM, Frick KD. Value based medicine.[comment]. Br J Ophthalmol 2005;89:643-4; author reply 644.
46. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
47. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583
48. National Institute for Health and Clinical Excellence. Macular degeneration (age-related)-pegaptanib and ranibizumab. Final appraisal determination [Internet]. [cited 2009 February 02]. Available at: http://www.nice.org.uk/guidance/index.jsp?action=download&o=40254.
49. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis?. Am J Ophthalmol 2006;142:141-143 (Pubitemid 43946805)
50. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002 e1-12.
51. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047 (Pubitemid 40797459)
52. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr., Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578 (Pubitemid 46579387)
53. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modeling cost effectiveness. Br J Ophthalmol 2007;91:1244-1246